Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices

N/ACompletedNCT01923064

Shanghai Zhongshan Hospital96 enrolled

Overview

The purpose of this randomized study to compare effect of endoscopic injection of a mixture of cyanoacrylate and lipiodol versus cyanoacrylate and lauromacrogol in gastric varices.

Gastroesophageal variceal bleeding is known as one of the most frequent death causes of patients with portal hypertension. When a patient has a bleeding episode, if no further prophylactic treatments is given, it's very likely that he/she will develop another rebleeding event in the future and maybe a terminal event. Gastric varices occur in 18-70% of patients with portal hypertension, which appear to be more severe, to require more transfusion and to have a higher mortality rate than esophageal variceal bleeding, with a high rate of rebleeding(38-89%). It has been recommended to use endoscopic cyanoacrylate injection as the first line treatment for hemostasis and secondary prophylaxis for gastric varices by general consensus. However, the efficacy and prevalence of complications between mixture of cyanoacrylate + lipiodol and cyanoacrylate + lauromacrogol have not yet been explored and reported. We conducted this study to evaluate the effect of endoscopic injection of a mixture of cyanoacrylate and lipiodol versus cyanoacrylate and lauromacrogol in gastric varices.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Gastric Varices Portal Hypertension

Interventions

LipiodolDRUG

endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices

LauromacrogolDRUG

endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients presented to our hospital with acute gastric variceal bleeding, with or without liver cirrhosis. * The age of the patients range from 18 to 80 years old. Exclusion Criteria: * Patients who have contraindications for cyanoacrylate, lipiodol or lauromacrogol therapy. * Patients who have abnormal portosystemic shunt according to the imaging results. * Patients who have no previous upper gastrointestinal bleeding history. * Patients who have multiple endoscopic treatments for esophagogastric varices before.

Locations (1)

Zhongshan Hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

bleeding rate of the puncture site

We tend to observe the immediate puncture site bleed on the injection of cyanoacrylate and lipiodol or lauromacrogol and withdrawal of needle catheter during endoscopic treatment of gastric varices.

Time frame: time period since the beginning of the injection, until up to 24 hours after the procedure

Secondary Outcomes

Rebleeding rate after endoscopic treatment

Patients were followed up for 6 months to see if they experience relapse of bleeding, presenting melena, haematemesis or both.

Time frame: 6 months from the date of enrollment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.